Rekombinanter Nerve Growth Factor Antikörper

Produktnummer ABIN7543390

Dieses Anti-Nerve Growth Factor-Antikörper ist ein Kaninchen Chimeric-Antikörper zur Detektion von Nerve Growth Factor in ELISA, BP, Crys, in vitro, in vivo und Inh. Geeignet für Human.

Kurzübersicht für Rekombinanter Nerve Growth Factor Antikörper (ABIN7543390)

Target: Nerve Growth Factor (NGF)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Chimeric

Konjugat: Dieser Nerve Growth Factor Antikörper ist unkonjugiert

Applikation: ELISA, Blocking Peptide (BP), Crystallization (Crys), In vitro Assay (in vitro), In vivo Studies (in vivo), Inhibition (Inh)

Klon: 911

Produktdetails anti-Nerve Growth Factor Antikörper

Verwendungszweck: Anti-Nerve growth factor [mab 911], Rabbit IgG, kappa

Spezifität: The antibody is specific for NGF. The NGF epitope is composed of β-strand segments from both NGF monomers. NGF is involved primarily in the growth, as well as the maintenance, proliferation, and survival of nerve cells (neurons).

Kreuzreaktivität: Maus

Produktmerkmale:

Original Species of Ab: Mouse

Original Format of Ab: IgG1

Aufreinigung: Protein A affinity purified

Isotyp: IgG kappa

Anwendungsinformationen

Applikationshinweise: The specificity of the original format of the antibody to NGF was confirmed by ELISA analysis (EC50 = 0.37 nM). The antibody was evaluated for its ability to block the binding of hNGF to the TrkA and p75 NGF receptors in various in vitro assays, such as blocking of TrkA autophosphorylation and blocking of NGF-dependent survival of dorsal root ganglion sensory neurons. The antibody was a potent blocker of all activities (Hongo et al., 2000, PMID: 10952410). In vivo administration of the antibody significantly reduces bone cancer pain behaviors (Sevcik et al., 2005, PMID: 15836976 and Halvorson et al., 2005, PMID: 16230406 and Buehlmann et al., 2019, PMID: 30161041) and fracture pain-related behaviors (Koewler et al., 2007, PMID: 17638576). The structure of Nerve Growth factor in complex with the Fab fragment was determined. Library Scanning Mutagenesis method was used to convert the original antibody in the humanized antibody tanezumab. The antibody bound human and murine NGF with high affinity (KD ~10 nM). Tanezumab and the original antibody blocked both TrkA and p75NTR binding to NGF and inhibited NGF-dependent neuron survival. Tanezumab inhibited NGFdependent survival with an IC50 of 15 pM, under the same conditions, 911 inhibited NGF with an IC50 of 400 pM (La Porte et al., 2014, PMID: 24830649). Preventative and therapeutic treatment with the antibody significantly prevented, or reversed, MIA-induced pain behaviour in osteoarthritis (Xu et al., 2016, PMID: 27208420).

Kommentare:

This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format for improved compatibility with existing reagents assays and techniques.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Details zu Nerve Growth Factor

Target: Nerve Growth Factor (NGF)

Andere Bezeichnung: Nerve growth factor

Hintergrund: Beta-nerve growth factor, Beta-NGF

UniProt: P01138

Pathways: Regulation of Cell Size